Study protocol: developing, disseminating, and implementing a core outcome set for selective fetal growth restriction in monochorionic twin pregnancies.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
09 Jan 2019
Historique:
received: 19 07 2018
accepted: 18 12 2018
entrez: 11 1 2019
pubmed: 11 1 2019
medline: 8 5 2019
Statut: epublish

Résumé

Selective fetal growth restriction in monochorionic twin pregnancies is associated with an increased risk of perinatal mortality and morbidity and represents a clinical dilemma. Interventions include expectant management with early preterm delivery if there are signs of fetal compromise, selective termination of the compromised twin, fetoscopic laser coagulation of the communicating placental vessels or termination of the whole pregnancy. Previous studies evaluating interventions have reported many different outcomes and outcome measures. Such variation makes comparing, contrasting, and combining results challenging, limiting ongoing research on this uncommon condition to inform clinical practice. We aim to produce, disseminate, and implement a core outcome set for selective fetal growth restriction research in monochorionic twin pregnancies. An international steering group, including professionals, researchers, and lay experts, has been established to oversee the development of this core outcome set. The methods have been guided by the Core Outcome Measures in Effectiveness Trials Initiative Handbook. Potential core outcomes will be developed by undertaking a systematic review of studies evaluating interventions for selective fetal growth restriction in monochorionic twin pregnancies. Potential core outcomes will be entered into a three-round Delphi survey and key stakeholders including clinical professionals, researchers, and lay experts will be invited to participate. Repeated reflection and rescoring of individual outcomes should encourage group and individual stakeholder convergence towards consensus outcomes which will be entered into a modified Nominal Group Technique to finalize the core outcome set. Once core outcomes have been agreed, we will establish standardized definitions and recommend high-quality measurement instruments for each outcome. The development, dissemination, and implementation of a core outcome set for selective fetal growth restriction should ensure that future research protocols select, collect, and report outcomes and outcome measures in a standardized manner. Data synthesis will be possible on a broad level and rigorous implementation should advance the quality of research studies and their effective use in order to guide clinical practice, improve patient care, maternal, short-term perinatal outcomes, and long-term neurodevelopmental outcomes. Core Outcome Measures in Effectiveness Trials (COMET) registration number: 998. International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD42018092697 . 18th April 2018.

Sections du résumé

BACKGROUND BACKGROUND
Selective fetal growth restriction in monochorionic twin pregnancies is associated with an increased risk of perinatal mortality and morbidity and represents a clinical dilemma. Interventions include expectant management with early preterm delivery if there are signs of fetal compromise, selective termination of the compromised twin, fetoscopic laser coagulation of the communicating placental vessels or termination of the whole pregnancy. Previous studies evaluating interventions have reported many different outcomes and outcome measures. Such variation makes comparing, contrasting, and combining results challenging, limiting ongoing research on this uncommon condition to inform clinical practice. We aim to produce, disseminate, and implement a core outcome set for selective fetal growth restriction research in monochorionic twin pregnancies.
METHODS METHODS
An international steering group, including professionals, researchers, and lay experts, has been established to oversee the development of this core outcome set. The methods have been guided by the Core Outcome Measures in Effectiveness Trials Initiative Handbook. Potential core outcomes will be developed by undertaking a systematic review of studies evaluating interventions for selective fetal growth restriction in monochorionic twin pregnancies. Potential core outcomes will be entered into a three-round Delphi survey and key stakeholders including clinical professionals, researchers, and lay experts will be invited to participate. Repeated reflection and rescoring of individual outcomes should encourage group and individual stakeholder convergence towards consensus outcomes which will be entered into a modified Nominal Group Technique to finalize the core outcome set. Once core outcomes have been agreed, we will establish standardized definitions and recommend high-quality measurement instruments for each outcome.
DISCUSSION CONCLUSIONS
The development, dissemination, and implementation of a core outcome set for selective fetal growth restriction should ensure that future research protocols select, collect, and report outcomes and outcome measures in a standardized manner. Data synthesis will be possible on a broad level and rigorous implementation should advance the quality of research studies and their effective use in order to guide clinical practice, improve patient care, maternal, short-term perinatal outcomes, and long-term neurodevelopmental outcomes.
TRIAL REGISTRATION BACKGROUND
Core Outcome Measures in Effectiveness Trials (COMET) registration number: 998. International Prospective Register of Systematic Reviews (PROSPERO) registration number: CRD42018092697 . 18th April 2018.

Identifiants

pubmed: 30626413
doi: 10.1186/s13063-018-3153-y
pii: 10.1186/s13063-018-3153-y
pmc: PMC6327411
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

35

Références

Ultrasound Obstet Gynecol. 2007 Jul;30(1):28-34
pubmed: 17542039
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Fetal Diagn Ther. 2010;27(3):121-33
pubmed: 20413975
Implement Sci. 2010 Nov 22;5:91
pubmed: 21092164
J Clin Epidemiol. 2011 Apr;64(4):395-400
pubmed: 21194891
PLoS Med. 2011 Jan 25;8(1):e1000393
pubmed: 21283604
Am J Obstet Gynecol. 1990 May;162(5):1230-6
pubmed: 2187353
Prenat Diagn. 2013 Feb;33(2):109-15
pubmed: 23280487
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
BJOG. 2014 Sep;121(10):1181-2
pubmed: 24889142
Trials. 2014 Jun 25;15:247
pubmed: 24962012
Fetal Diagn Ther. 2016;39(3):186-91
pubmed: 26344150
Am J Obstet Gynecol. 2016 Apr;214(4):452-464
pubmed: 26778385
BJOG. 2016 Sep;123(10):1599
pubmed: 27428666
Curr Opin Obstet Gynecol. 2016 Dec;28(6):485-491
pubmed: 27755130
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
Ultrasound Obstet Gynecol. 2017 Nov;50(5):559-568
pubmed: 27859836
Pregnancy Hypertens. 2016 Oct;6(4):274-278
pubmed: 27939467
BMJ Open. 2016 Dec 21;6(12):e013998
pubmed: 28003300
Contraception. 2017 May;95(5):437-441
pubmed: 28065833
BJOG. 2017 Sep;124(10):1481-1489
pubmed: 28421657
BJOG. 2017 Nov;124(12):1829-1839
pubmed: 28432737
Semin Fetal Neonatal Med. 2017 Dec;22(6):376-382
pubmed: 28532678
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
Trials. 2017 Jul 14;18(1):325
pubmed: 28709445
Int J Gynaecol Obstet. 2017 Dec;139(3):262-267
pubmed: 28803445
BJOG. 2018 Jun;125(7):795-803
pubmed: 29030992
Ultrasound Obstet Gynecol. 2019 Jan;53(1):47-54
pubmed: 29363848
Ultrasound Obstet Gynecol. 2018 Nov;52(5):577-585
pubmed: 29607558
BMJ Paediatr Open. 2017 Jul 26;1(1):e000048
pubmed: 29637104
Best Pract Res Clin Obstet Gynaecol. 2018 May;49:79-88
pubmed: 29661565

Auteurs

Asma Khalil (A)

Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK. akhalil@sgul.ac.uk.
Fetal Medicine Unit, Department of Obstetrics and Gynaecology, St. George's University Hospitals NHS Foundation Trust, Blackshaw Road, London, SW17 0QT, UK. akhalil@sgul.ac.uk.

James M N Duffy (JMN)

Balliol College, University of Oxford, Broad Street, Oxford, OX1 3BJ, UK.
Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, UK.

Helen Perry (H)

Vascular Biology Research Centre, Molecular and Clinical Sciences Research Institute, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK.
Fetal Medicine Unit, Department of Obstetrics and Gynaecology, St. George's University Hospitals NHS Foundation Trust, Blackshaw Road, London, SW17 0QT, UK.

Wessel Ganzevoort (W)

Department of Obstetrics and Gynecology, Academic Medical Center Amsterdam, University of Amsterdam, Amsterdam, The Netherlands.

Keith Reed (K)

Twin and Multiple Births Association (TAMBA), The Manor House Manor Park, Church Hill, Aldershot, GU12 4JU, UK.

Ahmet A Baschat (AA)

The Johns Hopkins Center for Fetal Therapy, 600 North Wolfe, Nelson 228, Baltimore, MD, 21287, USA.

Jan Deprest (J)

Department of Obstetrics and Gynecology, University Hospitals of KU Leuven, Herestraat, 49 3000, Leuven, Belgium.

Eduardo Gratacos (E)

Barcelona Center for Maternal-Fetal and Neonatal Medicine, Hospital Clínic and Hospital Sant Joan de Deu, Universitat de Barcelona; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and Centre for Biomedical Research on Rare Diseases (CIBER-ER), Barcelona, Spain.

Kurt Hecher (K)

Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf, Neues Klinikum, Gebäude O10 Martinistr. 52, 20246, Hamburg, Germany.

Liesbeth Lewi (L)

Department of Obstetrics and Gynecology, University Hospitals of KU Leuven, Herestraat, 49 3000, Leuven, Belgium.

Enrico Lopriore (E)

Division of Fetal Medicine, Department of Obstetrics, Leiden University Medical Center, K-06-35, P.O. Box 9600, 2300RC, Leiden, The Netherlands.

Dick Oepkes (D)

Division of Fetal Medicine, Department of Obstetrics, Leiden University Medical Center, K-06-35, P.O. Box 9600, 2300RC, Leiden, The Netherlands.

Aris Papageorghiou (A)

Fetal Medicine Unit, Department of Obstetrics and Gynaecology, St. George's University Hospitals NHS Foundation Trust, Blackshaw Road, London, SW17 0QT, UK.

Sanne J Gordijn (SJ)

Department of Obstetrics and Gynecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH